GeneNovate Investors' Day

The importance of gene and cell therapies as well as tissue therapeutics (Advanced Therapy Medicinal Products) is steadily increasing worldwide. In particular, patients with rare diseases - at least affecting 4 million people in Germany - and otherwise untreatable cancer patients can benefit from treatment in the long term. Technological advances, such as the expansion of the use of artificial intelligence, are further dynamizing the field.

Sixteen gene therapies and one cell therapy are currently approved in Europe (as of December 2024, vfa). The number of clinical trials worldwide is constantly increasing. Groundbreaking developments are on the horizon for this innovative business field, with sales of up to EUR 27.9 billion expected by 2026. The German government has also recognized the potential of these innovative therapies. In a National Strategy for Gene- and Cell-Based Therapies, concrete measures have been defined to improve the framework conditions, e.g. in research and development, regulation or manufacturing practice.  One initiative is the GeneNovate Entrepreneurship Programme in the field of gene and cell therapies, which, for the second time in 2025, prepares participants from research and science who are interested in founding a company for the topic of spin-offs from the academic environment and accompanies them for six months. Bringing together different stakeholders is another key pillar of the strategy to facilitate the dialogue across disciplinary, sectoral, regional and national boundaries and thus accelerates translation.

This is where the GeneNovate Investors' Day comes in: without smart investments and relevant expert mentoring, no new therapies! GeneNovate Investors' Day is a networking event for scientific, translationally oriented project teams, international startups, investors and experts from science, industry and politics. Discover with us the latest developments in the field of gene and cell therapies and promising investment opportunities.  Find out more in exciting panels on key topics such as the particular features of the value chain, investment specifics or international best practices. In the heart of Berlin, we create the right atmosphere for personal exchange!

GeneNovate: Entrepreneurship programme for gene and cell therapies (GCT)

GeneNovate is the first national entrepreneurship programme in the field of gene and cell therapies (GCT). The target group includes people in the early career phase, such as advanced students, doctoral candidates and postdocs, as well as experienced researchers and doctors. Participants are accompanied by various mentors and go through six modules in which they receive comprehensive information on topics such as Business Models, IP Protection, Regulation, Go to Market, Legal Foundations, Team & Project Management, Finance & Funding or Exit Options & Strategic Value.

GeneNovate was launched in January 2024 as a supra-regional pilot project in Berlin, Mainz and Munich in cooperation with the National Network Office for Gene and Cell Therapies (GCT), the Berlin Institute of Health at Charité (BIH), Charité - Universitätsmedizin Berlin, Johannes Gutenberg University Mainz (JGU), University Medical Centre Mainz, Life Science Zentrum Mainz GmbH, TUM Technical University Munich, TUMVenture Labs Healthcare, UnternehmerTUM, MRI Klinikum rechts der Isar.

Please find further information on the GeneNovate Website.